vatalanib has been researched along with imatinib mesylate in 19 studies
| Studies (vatalanib) | Trials (vatalanib) | Recent Studies (post-2010) (vatalanib) | Studies (imatinib mesylate) | Trials (imatinib mesylate) | Recent Studies (post-2010) (imatinib mesylate) |
|---|---|---|---|---|---|
| 276 | 42 | 98 | 11,477 | 960 | 5,773 |
| Protein | Taxonomy | vatalanib (IC50) | imatinib mesylate (IC50) |
|---|---|---|---|
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | 0.31 | |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 0.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (73.68) | 29.6817 |
| 2010's | 5 (26.32) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M | 1 |
| Briesewitz, R; Bruner, RJ; Caligiuri, MA; Griffin, JH; Leung, J | 1 |
| Shiotsu, Y | 1 |
| Kindler, HL | 1 |
| Koskinen, PK; Krebs, R; Lemström, KB; Nykänen, AI; Raisky, O; Sihvola, R; Tikkanen, JM; Wood, J | 1 |
| Salmons, B | 1 |
| Borner, MM | 1 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Hollmén, M; Koskinen, PK; Lemström, KB; Nykänen, AI; Tikkanen, JM; Wood, J | 1 |
| Furuhashi, M; Hasumi, Y; Heldin, CH; Hellberg, C; Kłosowska-Wardega, A; Ostman, A | 1 |
| Bono, P; Bosselli, S; Casali, PG; Coco, P; De Braud, F; De Pas, T; Jalava, T; Joensuu, H; Laurent, D; Putzu, C; Spreafico, C | 1 |
| Bui, B; Italiano, A | 1 |
| Apice, G; Bruni, GS; Caponigro, F; Iaffaioli, RV; Milano, A | 1 |
| Beumer, JH; Desjardins, A; Egorin, MJ; Friedman, HS; Gururangan, S; Herndon, JE; Lagattuta, TF; Reardon, DA; Salvado, AJ; Vredenburgh, JJ | 1 |
| Brennan, CW; Fomchenko, EI; Fujii, K; Holland, EC; Huse, JT; Ladanyi, M; Levine, RL; Nakada, M; Oka, H; Ozawa, T; Pedraza, A; Sasayama, T; Squatrito, M; Tandon, A; Utsuki, S; Wang, L; Yasui, Y | 1 |
| Åhgren, A; Hasumi, Y; Heldin, CH; Hellberg, C; Kłosowska-Wardęga, A | 1 |
| Burris, H; Doss, H; Greco, FA; Hainsworth, J; Infante, J; Jones, S; Spigel, D; Thompson, D | 1 |
| Aglietta, M; Bono, P; Boselli, S; Casali, PG; Coco, P; De Braud, F; De Pas, T; Grignagni, G; Jalava, T; Joensuu, H; Kappeler, C; Laurent, D; Spitalieri, G; Spreafico, C; Toffalorio, F | 1 |
| Hirt, SW; Keil, L; Lehle, K; Schaub, AL; Schmid, C; von Suesskind-Schwendi, M | 1 |
6 review(s) available for vatalanib and imatinib mesylate
| Article | Year |
|---|---|
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
Moving beyond chemotherapy: novel cytostatic agents for malignant mesothelioma.
Topics: Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Mesothelioma; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Vascular Endothelial Growth Factor A | 2004 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
Topics: Antineoplastic Agents; Benzamides; Chemotherapy, Adjuvant; Dioxoles; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Neoadjuvant Therapy; Niacinamide; Oligonucleotides; Phthalazines; Piperazines; Proto-Oncogene Mas; Pyridines; Pyrimidines; Pyrroles; Sunitinib; Tetrahydroisoquinolines; Trabectedin | 2006 |
4 trial(s) available for vatalanib and imatinib mesylate
| Article | Year |
|---|---|
Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Proteins; Phthalazines; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy | 2008 |
Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Brain Neoplasms; Female; Glioblastoma; Glioma; Humans; Hydroxyurea; Imatinib Mesylate; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Phthalazines; Piperazines; Pyridines; Pyrimidines; Recurrence; Treatment Outcome | 2009 |
A phase I trial to determine the safety of imatinib in combination with vatalanib in patients with advanced malignancies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Drug Administration Schedule; Female; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Phthalazines; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Risk Assessment; Tennessee; Time Factors; Treatment Outcome; Young Adult | 2011 |
Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Phthalazines; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sunitinib | 2011 |
9 other study(ies) available for vatalanib and imatinib mesylate
| Article | Year |
|---|---|
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases | 2007 |
Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome.
Topics: Adult; Amino Acid Sequence; Animals; Antineoplastic Agents; Base Sequence; Benzamides; Blotting, Western; Cell Division; Cell Line; Cell Survival; Cell Transformation, Neoplastic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Eosinophils; Gene Deletion; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Indoles; Male; Mice; Models, Chemical; Models, Genetic; Molecular Sequence Data; Peptides; Phthalazines; Piperazines; Precipitin Tests; Protein Structure, Tertiary; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Recombinant Fusion Proteins; Recurrence; Tyrosine | 2003 |
Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation.
Topics: Angiogenesis Inhibitors; Animals; Arteriosclerosis; Benzamides; Graft Rejection; Heart Transplantation; Imatinib Mesylate; Inflammation; Male; Muscle, Smooth, Vascular; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Postoperative Complications; Pyridines; Pyrimidines; Rats; Rats, Inbred Strains; Rats, Inbred WF; Receptors, Platelet-Derived Growth Factor; RNA, Messenger; Transplantation, Homologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Phacilitate Cell and Gene Therapy Forum 2005. Cell and gene therapy: a corporate perspective. 24-26 January 2005, Washington, DC, USA.
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Cell- and Tissue-Based Therapy; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diphosphonates; Entrepreneurship; Genetic Therapy; Humans; Imatinib Mesylate; Imidazoles; Molecular Structure; Phthalazines; Piperazines; Pyridines; Pyrimidines; Zoledronic Acid | 2005 |
Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease.
Topics: Animals; Benzamides; Bronchiolitis Obliterans; Drug Therapy, Combination; Glycoproteins; Imatinib Mesylate; Lymphatic Vessels; Male; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Rats; Rats, Inbred Strains; Receptors, Amino Acid; Trachea; Transplantation, Homologous; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
Topics: Angiogenesis Inducing Agents; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Imatinib Mesylate; Immunohistochemistry; Melanoma, Experimental; Mice; Pericytes; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2007 |
PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas.
Topics: Amino Acid Sequence; Base Sequence; Benzamides; Gene Dosage; Gene Fusion; Gene Rearrangement; Glioblastoma; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinases; Molecular Sequence Data; Mutation; Oligodendroglioma; Phosphatidylinositol 3-Kinases; Phosphorylation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Transformation, Genetic | 2010 |
Combination therapy using imatinib and vatalanib improves the therapeutic efficiency of paclitaxel towards a mouse melanoma tumor.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Imatinib Mesylate; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Paclitaxel; Phthalazines; Piperazines; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-sis; Pyridines; Pyrimidines; RNA, Small Interfering; Signal Transduction | 2011 |
Synergism of imatinib, vatalanib and everolimus in the prevention of chronic lung allograft rejection after lung transplantation (LTx) in rats.
Topics: Animals; Bronchiolitis Obliterans; Drug Synergism; Everolimus; Fibrosis; Graft Rejection; Imatinib Mesylate; Immunohistochemistry; Lung Transplantation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Inbred F344; Rats, Inbred WKY; Receptor Protein-Tyrosine Kinases; Receptor, Platelet-Derived Growth Factor alpha; TOR Serine-Threonine Kinases; Transplantation, Homologous; Vascular Endothelial Growth Factor Receptor-2 | 2019 |